The number of pertussis cases in Japan has decreased dramatically following the
nationwide use of an acellular pertussis vaccine combined with diphtheria-tetanus toxoids …

In 2008, the number of pertussis cases increased substantially among Japanese
adolescents, despite high coverage with acellular pertussis vaccine (DTaP). This study …

Of 342 cases with pertussis notified from 1986 through 1989 in Aichi Prefecture, Japan, 331
(96.8%) were unimmunized children. To confirm the clinical efficacy of the acellular pertussis …

In Japan, the morbidity rate for pertussis per 100,000 population was 147.6 in 1950 when
whole cell pertussis vaccine was introduced but dropped to 0.2 in 1972 when routine …

A double blind, randomized, controlled trial compared the safety and immunogenicity of an
acellular pertussis vaccine formulated at Lederle using the Takeda acellular pertussis …

Objective. This case-control study investigated the protective efficacy against pertussis of
three doses of a two-component acellular pertussis vaccine (manufactured by Biken in …

Acellular pertussis diphtheria, tetanus vaccine (APDT) was licensed in 1981 in Japan. This
vaccine contains pertussis toxin (PT), filamentous hemagglutinin (FHA) and agglutinogen …

The objective of this open study was to monitor the long-term effectiveness of the Lederle-
Takeda diphtheria and tetanus toxoids and acellular pertussis antigen (s)(DTaP) vaccine …

Background: Real evaluation of any vaccine can only be done after the vaccine has been in
routine use for a substantially long period of time. In Japan, acellular pertussis vaccine was …

The recent increase of pertussis in young adults in Japan is hypothesized to be due in part
to waning protection from the acellular pertussis vaccine. While a booster immunization may …